Abstract:Aminopeptidase N (APN, CD13) is closely associated with the development and progression of cancer. Previous studies suggested APN as a biomarker for cancer stem cells. APN inhibitors have been intensively evaluated as chemosensitizers for cancer treatments. In the present study, tetrahydro- β -carboline scaffold was introduced to the structure of APN inhibitors. The synthesized compounds showed potent enzyme inhibitory activities compared with Bestatin, an approved APN inhibitor, in cell-based enzymatic assay. In combination with chemotherapeutic drugs, representative APN inhibitor molecules D12 , D14 and D16 significantly improved the antiproliferative potency of anticancer drugs in the in vitro tests. Further mechanistic studies revealed that the anticancer effects of these drug combinations are correlated with decreased APN expression, increased ROS level, and induction of cell apoptosis. The spheroid-formation assay and colony-formation assay results showed effectiveness of Paclitaxel-APN inhibitor combination against breast cancer stem cell growth. The combined drug treatment led to reduced mRNA expression of OCT-4, SOX-2 and Nanog in the cancer stem cells tested, suggesting the reduced stemness of the cells. In the in vivo study, the selected APN inhibitors, especially D12 , exhibited improved anticancer activity in combination with Paclitaxel compared with Bestatin. Collectively, potent APN inhibitors were discovered, which could be used as lead compounds for tumor chemo-sensitization and cancer stem cell-based therapies.

Discovery of a Novel Aminopeptidase N Inhibitor Dino-Leucine Borate

Novel Leucine Ureido Derivatives As Inhibitors of Aminopeptidase N (APN).

Novel Leucine Ureido Derivatives As Aminopeptidase N Inhibitors Using Click Chemistry

Design, Synthesis and Biological Evaluation of Novel Amino Acid Ureido Derivatives As Aminopeptidase N/CD13 Inhibitors

Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN).

Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.

Novel Leucine Ureido Derivatives As Aminopeptidase N Inhibitors. Design, Synthesis and Activity Evaluation.

Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

A Novel Aminopeptidase N Inhibitor Developed by Virtual Screening Approach

Novel Aminopeptidase N (APN/CD13) Inhibitors Derived from 3-Phenylalanyl-n'-substituted-2,6-piperidinedione.

Novel 3-Phenylpropane-1,2-diamine Derivates As Inhibitors of Aminopeptidase N (APN).

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.

Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors.

Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions

Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers

Synthesis of a Novel Series of L-isoserine Derivatives As Aminopeptidase N Inhibitors

Design,synthesis and Bioactivity Evalution of N-substituted-2,6-dioxopiperidin Derivatives As Aminopeptidase N(APN/CD13) Inhibitors

LJNK, an indoline-2,3-dione-based aminopeptidase N inhibitor with promising antitumor potency.

Recent advance in aminopeptidase N (APN/CD13) inhibitor research.

Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.